Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) Return on Equity (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Return on Equity for 3 consecutive years, with 0.51% as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Return on Equity fell 35.0% year-over-year to 0.51%, compared with a TTM value of 0.51% through Sep 2021, down 35.0%, and an annual FY2020 reading of 0.5%, changed N/A over the prior year.
  • Return on Equity was 0.51% for Q3 2021 at Black Diamond Therapeutics, down from 0.39% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.66% in Q4 2019 and bottomed at 0.51% in Q3 2021.
  • Average Return on Equity over 3 years is 0.16%, with a median of 0.22% recorded in 2020.
  • The sharpest move saw Return on Equity crashed -87bps in 2020, then dropped -4bps in 2021.
  • Year by year, Return on Equity stood at 0.66% in 2019, then tumbled by -131bps to 0.21% in 2020, then crashed by -147bps to 0.51% in 2021.
  • Business Quant data shows Return on Equity for BDTX at 0.51% in Q3 2021, 0.39% in Q2 2021, and 0.28% in Q1 2021.